Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Antibiotic Spring? Regulatory Incentives Spur Activity – And Maybe Medical Advances

Jul 12 2017

• By Bridget Silverman

Antibiotic resistant bacteria closeup biofilm

Related Content

Industry Welcomes EU’s Latest AMR Action Plan, But Public Health Advocates Remain Skeptical

Jul 03 2017

White House Antibiotic Plan Takes Top-Down Approach To Boosting Research

Mar 27 2015

EU Takes ‘Holistic’ Approach To Diagnosing And Tackling AMR

Jul 03 2017

‘Wildcard’ Patents: Why A REVAMP-ed Proposal Might Work In 2017

Nov 17 2016

EU, US & Japan Tackle Difficulties With Randomized Trials Involving Multi-Drug Resistant Bacteria

Jun 20 2017

Antibiotic Incentives: Pfizer’s Read Touts Exclusivity Voucher

Mar 29 2017

Antibiotic Development: Limited Population Pathway In US Removes Barrier

Mar 29 2017

AMR Threat Prompts EU, US And Japan To Join Forces To Align Data Requirements For New Drug Developers

Jun 13 2017

Pharma's Latest Davos Pledge: Sincere, Or Just Keeping Up Appearances?

Jan 18 2017

CARB-X Partnership Puts Antibiotics' Future In Biotech Startups' Hands

Jul 30 2016

Antibiotics Pipeline Is Lively, But Sponsors Are Fragile

Jul 04 2017

Related Companies

Achaogen, Inc.

Insmed Incorporated

Shionogi & Co. Ltd.

Melinta Therapeutics, Inc.

Nabriva Therapeutics plc.

Entasis Therapeutics Holdings Inc.

Polyphor AG

Debiopharm S.A.

Destiny Pharma plc

Additional Topics

United States Clinical Trials Review Pathway Approvals Regulation Infectious Diseases BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window